NASDAQ · Biotechnology

Galectin Therapeutics Inc. (GALT) Stock

$3.94 +8.24% NASDAQ: GALT Healthcare

Valuation

MetricValue
Price$3.94
Market Cap$259.48M
P/E Ratio-8.45
P/B Ratio-1.74
P/S Ratio0.00
EPS (TTM)$-0.48
52-Week High$7.13
52-Week Low$2.03
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE21.48%
ROA-187.80%
ROCE11.42%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity-1.01
Current Ratio2.38

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-30.0M$-38.0M$-38.0M$-42.0M$-20.0M
Net Profit$-31.0M$-39.0M$-41.0M$-47.0M$-31.0M
EPS$-0.52$-0.65$-0.74$-0.76$-0.48
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$42.0M$21.0M$28.0M$17.0M$20.0M
Total Liabilities$39.0M$53.0M$88.0M$121.0M$146.0M
Cash$40.0M$19.0M$26.0M$15.0M$18.0M
Borrowings$29.0M$40.0M$72.0M$106.0M$134.0M

Latest News

GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH Zacks · Jun 24, 2026 GALT Stock Surges 22% — On Track For Best Day In Over A Year After FDA Clears Path For Late-Stage Belapectin Trial Stocktwits · Jun 23, 2026 Galectin Therapeutics Says FDA Alignment Reached on Phase 3 Belapectin Trial MT Newswires · Jun 23, 2026 Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension GlobeNewswire · Jun 23, 2026 Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis GlobeNewswire · May 27, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-24.0M$-31.0M$-33.0M$-42.0M$-24.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$0$10.0M$0$0
Net Cash Flow$13.0M$-21.0M$7.0M$-11.0M$3.0M
Free Cash Flow$-24.0M$-31.0M$-33.0M$-42.0M$-24.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.21
EV / EBITDA-26.33
FCF Yield-6.68%
Quick Ratio0.10
Interest Coverage-2.02
Return 1Y22.34%
Return 3Y116.98%
Return 5Y78.95%

Ownership

Insiders Held29.09%
Institutions Held21.17%
Institutions Float Held29.86%
Institutional HolderSharesReport Date
Vanguard Capital Management LLC1,966,5422026-03-31
Marshall Wace LLP1,219,9122026-03-31
Osaic Holdings Inc.1,122,6702026-03-31
Blackrock Inc.799,2372026-03-31
Millennium Management Llc798,4342026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALTAltimmune, Inc. $2.61 +0.38% -3.42 $507.58M 0.00%
AURAAura Biosciences, Inc. $6.54 +0.54% -3.42 $676.47M 0.00%
DMACDiaMedica Therapeutics Inc. $8.33 +4.00% -11.43 $448.85M 0.00%
DRTSAlpha Tau Medical Ltd. $14.41 +2.93% -14.31 $1.30B 0.00%
DSGNDesign Therapeutics, Inc. $11.65 +1.39% -10.46 $727.62M 0.00%

About Galectin Therapeutics Inc.

Galectin Therapeutics Inc. is led by CEO Joel Lewis, employs 15 people, headquartered in US, publicly traded since 2002.

Galectin Therapeutics Inc. (GALT) stock trades at $3.94 with a market capitalization of $259.48M. The stock is valued at a price-to-earnings (P/E) ratio of -8.45, price-to-book of -1.74, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.03 and $7.13, and currently trades 44.7% below its 52-week high.

On profitability, Galectin Therapeutics Inc. generates a return on equity (ROE) of 21.48% — well above the market average, a sign of a high-quality business, return on capital employed of 11.42%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides